Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.48 |
| ▸ | PDE4A | P27815 | 9/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22588301 | 0.96 | APP (0.49) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22588418 | 0.90 | APP (0.48) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22604798 | 0.90 | APP (0.48) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22604724 | 0.86 | PDE4A (0.47) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22588415 | 0.85 | PDE4A (0.47) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22604625 | 0.82 | NPC1 (0.46) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22588396 | 0.81 | PDE4A (0.45) | APPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22588111 | 0.80 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22588382 | 0.75 | APP (0.54) | APPMAOBNPC1RAB9ATDP1 | |
| SCHEMBL22454181 | 0.75 | NAAA (0.56) | APPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| CN-113924298-A | Compounds comprising N-methyl-2-pyridone and pharmaceutically acceptable salts | 邓迪大学 | 2022-01-11 | — | — | CN | disclosed |
| WO-2020216779-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216779-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | TPMT, IL5, P2RY6 | APP 3492/4885PDE4A 1032/4885PDE4B 883/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | APP 3492/4885PDE4A 1032/4885PDE4B 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.